Abbott Laboratories logo
Abbott Laboratories (ABT)
Compare

Abbott Laboratories (ABT) PS Ratio: 3.44

Is Abbott Laboratories’s P/S ratio high or low?

Abbott Laboratories's P/S ratio of 3.44 is 28% below its 5-year average of 4.78, near the low end of its 5-year range (3.20–5.98).

The P/S ratio for Abbott Laboratories (ABT) is 3.44 as of Wednesday, June 10, 2026. It is below its 12-month average by 27.52% (4.75).

ABT PS Ratio Chart

ABT PS Ratio
3.44-37.79% 1Y
Zoom

ABT Average PS Ratio Chart

ABT Current vs Average PS Ratio Chart

ABT PS Ratio Metrics

PS RATIO

3.44

PS RATIO AVG TTM

4.75

PS RATIO AVG 3Y

4.81

PS RATIO AVG 5Y

4.78

PS RATIO AVG 10Y

4.58

PS RATIO AVG 15Y

3.78

PS RATIO AVG 20Y

3.19

CURRENT VS TTM AVG

-27.52%

CURRENT VS 3Y AVG

-28.41%

CURRENT VS 5Y AVG

-28.05%

CURRENT VS 10Y AVG

-24.94%

CURRENT VS 15Y AVG

-9.08%

CURRENT VS 20Y AVG

+7.85%

ABT Competitors' PS Ratio

NAMEMARKET CAPPS RATIOTTM3Y5Y
Abbott Laboratories (ABT)$154.66B3.444.754.814.78
Gilead Sciences, Inc. (GILD)$151.21B5.135.414.323.91
Intuitive Surgical, Inc. (ISRG)$146.44B14.0718.7319.8819.01
Pfizer Inc. (PFE)$146.36B2.322.322.452.86
Danaher Corporation (DHR)$130.25B5.296.026.596.43
Thermo Fisher Scientific Inc. (TMO)$179.45B3.994.394.674.97
Amgen Inc. (AMGN)$183.75B4.974.895.135.11
CVS Health Corporation (CVS)$125.16B0.310.250.240.31
Bristol-Myers Squibb Company (BMY)$114.14B2.362.212.312.70
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B9.149.6810.549.74

P/S vs. its own history

At 3.44, P/S is in its normal range — richer than 54% of its 20-year range.

20-year low

0.94

median

3.22

20-year high

7.12

cheaperricher

Sales Valuation

P/S Ratio

3.44

Market Cap / Annual Revenue

Abbott Laboratories PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Abbott Laboratories PS Ratio FAQ

What is the P/S ratio for Abbott Laboratories (ABT)?
The P/S ratio for ABT stock is 3.44.
Is Abbott Laboratories's P/S ratio high or low?
Abbott Laboratories's P/S ratio of 3.44 is 28% below its 5-year average of 4.78, near the low end of its 5-year range (3.20–5.98).
What is the TTM average P/S ratio for Abbott Laboratories (ABT)?
The TTM average P/S ratio for ABT stock is 4.75.
What is the 3Y average P/S ratio for Abbott Laboratories (ABT)?
The 3Y average P/S ratio for ABT stock is 4.81.
What is the 5Y average P/S ratio for Abbott Laboratories (ABT)?
The 5Y average P/S ratio for ABT stock is 4.78.
What is the 10Y average P/S ratio for Abbott Laboratories (ABT)?
The 10Y average P/S ratio for ABT stock is 4.58.
What is the 15Y average P/S ratio for Abbott Laboratories (ABT)?
The 15Y average P/S ratio for ABT stock is 3.78.
What is the 20Y average P/S ratio for Abbott Laboratories (ABT)?
The 20Y average P/S ratio for ABT stock is 3.19.

Abbott Laboratories PS Ratio History

DATEPS RATIO
2026-06-103.44
2026-06-093.53
2026-06-083.50
2026-06-053.53
2026-06-043.51
2026-06-033.37
2026-06-023.37
2026-06-013.40
2026-05-293.31
2026-05-283.34
2026-05-273.32
2026-05-263.35
2026-05-223.38
2026-05-213.40
2026-05-203.42
2026-05-193.44
2026-05-183.40
2026-05-153.27
2026-05-143.29
2026-05-133.24
2026-05-123.26
2026-05-113.20
2026-05-083.26
2026-05-073.37
2026-05-063.34
2026-05-053.37
2026-05-043.39
2026-05-013.46
2026-04-303.51
2026-04-293.54
2026-04-283.70
2026-04-273.66
2026-04-243.59
2026-04-233.64
2026-04-223.61
2026-04-213.65
2026-04-203.78
2026-04-173.82
2026-04-163.76
2026-04-154.00
2026-04-143.98
2026-04-133.97
2026-04-103.95
2026-04-094.05
2026-04-084.08
2026-04-074.01
2026-04-064.03
2026-04-024.05
2026-04-014.03
2026-03-314.05
2026-03-304.02
2026-03-274.10
2026-03-264.12
2026-03-254.13
2026-03-244.10
2026-03-234.13
2026-03-204.16
2026-03-194.22
2026-03-184.28
2026-03-174.36
2026-03-164.33
2026-03-134.26
2026-03-124.26
2026-03-114.35
2026-03-104.36
2026-03-094.44
2026-03-064.32
2026-03-054.38
2026-03-044.46
2026-03-034.48
2026-03-024.50
2026-02-274.59
2026-02-264.58
2026-02-254.52
2026-02-244.52
2026-02-234.54
2026-02-204.42
2026-02-194.48
2026-02-184.52
2026-02-174.48
2026-02-134.50
2026-02-124.45
2026-02-114.53
2026-02-104.48
2026-02-094.43
2026-02-064.42
2026-02-054.35
2026-02-044.32
2026-02-034.35
2026-02-024.36
2026-01-304.36
2026-01-294.23
2026-01-284.23
2026-01-274.32
2026-01-264.34
2026-01-234.29
2026-01-224.33
2026-01-214.82
2026-01-204.83
2026-01-164.86
2026-01-154.93
2026-01-144.99
2026-01-134.96
2026-01-124.97
2026-01-095.02
2026-01-085.03
2026-01-075.07
2026-01-065.10
2026-01-055.04
2026-01-024.95
2025-12-315.00
2025-12-305.02
2025-12-294.97
2025-12-264.98
2025-12-244.98
2025-12-234.97
2025-12-224.99
2025-12-195.00
2025-12-184.99
2025-12-175.05
2025-12-165.06
2025-12-155.12
2025-12-125.00
2025-12-114.92
2025-12-104.89
2025-12-094.84
2025-12-084.87
2025-12-054.99
2025-12-045.00
2025-12-035.00
2025-12-025.04
2025-12-015.11
2025-11-285.14
2025-11-265.13
2025-11-255.11
2025-11-245.07
2025-11-215.11
2025-11-204.95
2025-11-195.03
2025-11-185.19
2025-11-175.19
2025-11-145.21
2025-11-135.16
2025-11-125.14
2025-11-115.07
2025-11-105.02
2025-11-075.04
2025-11-064.98
2025-11-054.97
2025-11-045.02
2025-11-034.94
2025-10-314.93
2025-10-304.97
2025-10-294.96
2025-10-285.14
2025-10-275.17
2025-10-245.15
2025-10-235.13
2025-10-225.20
2025-10-215.18
2025-10-205.26
2025-10-175.22
2025-10-165.18
2025-10-155.26
2025-10-145.41
2025-10-135.34
2025-10-105.38
2025-10-095.41
2025-10-085.45
2025-10-075.40
2025-10-065.43
2025-10-035.47
2025-10-025.40
2025-10-015.42
2025-09-305.44
2025-09-295.41
2025-09-265.42
2025-09-255.41
2025-09-245.44
2025-09-235.52
2025-09-225.55
2025-09-195.53
2025-09-185.47
2025-09-175.45
2025-09-165.39
2025-09-155.33
2025-09-125.43
2025-09-115.39
2025-09-105.25
2025-09-095.36
2025-09-085.37
2025-09-055.40
2025-09-045.39
2025-09-035.37
2025-09-025.34
2025-08-295.39
2025-08-285.34
2025-08-275.34
2025-08-265.34
2025-08-255.36
2025-08-225.39
2025-08-215.36
2025-08-205.38
2025-08-195.33
2025-08-185.29
2025-08-155.35
2025-08-145.25
2025-08-135.26
2025-08-125.32
2025-08-115.34
2025-08-085.45
2025-08-075.36
2025-08-065.32
2025-08-055.31
2025-08-045.28
2025-08-015.17
2025-07-315.13
2025-07-305.22
2025-07-295.28
2025-07-285.21
2025-07-255.22
2025-07-245.18
2025-07-235.19
2025-07-225.19
2025-07-215.13
2025-07-185.10
2025-07-174.97
2025-07-165.44
2025-07-155.43
2025-07-145.45
2025-07-115.45
2025-07-105.51
2025-07-095.50
2025-07-085.50
2025-07-075.52
2025-07-035.55
2025-07-025.53
2025-07-015.62
2025-06-305.61
2025-06-275.54
2025-06-265.52
2025-06-255.67
2025-06-245.70
2025-06-235.50
2025-06-205.49
2025-06-185.46
2025-06-175.46
2025-06-165.53
2025-06-135.60
2025-06-125.63
2025-06-115.58
2025-06-105.53
2025-06-095.50
2025-06-065.51
2025-06-055.53
2025-06-045.49
2025-06-035.52
2025-06-025.51
2025-05-305.51
2025-05-295.48

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Park, IL
114,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford